Adverse events following pandemic influenza vaccine Pandemrix® reported in the French military forces-2009-2010

被引:32
|
作者
Mayet, Aurelie [1 ]
Ligier, Caroline [1 ]
Gache, Kristel [1 ]
Manet, Ghislain [1 ]
Nivoix, Philippe [2 ]
Dia, Aissata [2 ]
Haus-Cheymol, Rachel [1 ]
Verret, Catherine [1 ]
Duron, Sandrine [1 ]
Faure, Nina [2 ]
Piarroux, Martine [2 ]
De Laval, Frank [2 ]
Simon, Fabrice [3 ]
Decam, Christophe [2 ]
Chaudet, Herve [2 ]
Meynard, Jean-Baptiste [1 ]
Rapp, Christophe [4 ]
Deparis, Xavier [2 ]
Migliani, Rene [1 ]
机构
[1] Ecole Val de Grace, Dept Epidemiol & Sante Publ Nord, Paris, France
[2] Inst Med Trop Serv Sante Armees, Dept Epidemiol & Sante Publ Sud, Marseille, France
[3] Hop Instruct Armees Laveran, Serv Pathol Infect & Trop, Marseille, France
[4] Hop Instruct Armees Begin, Serv Pathol Infect & Trop, St Mande, France
关键词
Influenza; Military forces; Pandemic; Vaccine; Vaccine adverse event; GUILLAIN-BARRE-SYNDROME; A VIRUS;
D O I
10.1016/j.vaccine.2011.01.056
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: In the face of the A(H1N1) 2009 influenza pandemic, in October 2009 the French military health service (SSA) initiated a large vaccination campaign with Pandemrix (R) vaccine in the military forces. The aim of this study was to describe vaccine adverse events (VAE) reported during this campaign. Methods: VAE and the number of people vaccinated were surveyed by the SSA Epidemiological network across all military forces during the campaign, from October 2009 to April 2010. For each case, a notification form was completed, providing patient and clinical information. Three types of VAE were considered: non-serious, serious and unexpected. Results: There were 315.4 reported VAE per 100,000 vaccinations. Vaccination and VAE incidence rate peaks coincided with influenza epidemic peak in early December. The number of injected doses was 49,138, corresponding to a 14.5% vaccination coverage among military personnel, and 155 VAE were reported, including 5 serious VAE (1 Guillain-Barre syndrome, 2 malaises and 1 convulsive episode). Most VAE were non-serious (97.1%). Among these, 6 cases of local, rapidly regressive paresthesia were observed. Discussion: The military VAE surveillance system constitutes the only observatory on benign VAE in France. The reporting rate was much higher after the pandemic vaccine than after the seasonal vaccine, which may be a reflection of stimulated reporting. This report provides a useful description of VAE among military personnel during a mass emergency vaccination program, showing that the tolerance of the pandemic vaccine appeared acceptable. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2576 / 2581
页数:6
相关论文
共 50 条
  • [1] Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009-2010 season in the active component US military and civilians aged 17-44 years reported to the Vaccine Adverse Event Reporting System
    Bardenheier, Barbara H.
    Duderstadt, Susan K.
    Engler, Renata J. M.
    McNeil, Michael M.
    VACCINE, 2016, 34 (37) : 4406 - 4414
  • [2] Increase in reported adverse events following seasonal influenza vaccination among the French armed forces, 2008-2009: Possible role of stimulated reporting and background cases of influenza-like infection
    Mayet, A.
    Nivoix, P.
    Haus-Cheymol, R.
    De Laval, F.
    Verret, C.
    Duron, S.
    Faure, N.
    Piarroux, M.
    Decam, C.
    Chaudet, H.
    Meynard, J. -B.
    Deparis, X.
    Migliani, R.
    PUBLIC HEALTH, 2012, 126 (01) : 70 - 76
  • [3] Spontaneous reporting of adverse events following immunisation against pandemic influenza in Denmark November 2009-March 2010
    Folkenberg, Maja
    Callreus, Torbjorn
    Svanstrom, Henrik
    Valentiner-Branth, Palle
    Hviid, Anders
    VACCINE, 2011, 29 (06) : 1180 - 1184
  • [4] Serious adverse events following receipt of trivalent inactivated influenza vaccine in Korea, 2003-2010
    Choe, Young June
    Cho, Heeyeon
    Kim, Sung Nam
    Bae, Geun-Ryang
    Lee, Jong-Koo
    VACCINE, 2011, 29 (44) : 7727 - 7732
  • [5] Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010
    Vellozzi, Claudia
    Broder, Karen R.
    Haber, Penina
    Guh, Alice
    Nguyen, Michael
    Cano, Maria
    Lewis, Paige
    McNeil, Michael M.
    Bryant, Marthe
    Singleton, James
    Martin, David
    DeStefano, Frank
    VACCINE, 2010, 28 (45) : 7248 - 7255
  • [6] An analysis of national target groups for monovalent 2009 pandemic influenza vaccine and trivalent seasonal influenza vaccines in 2009-10 and 2010-11
    Ng, Sophia
    Wu, Peng
    Nishiura, Hiroshi
    Ip, Dennis K. M.
    Lee, Esther S. T.
    Cowling, Benjamin J.
    BMC INFECTIOUS DISEASES, 2011, 11
  • [7] An analysis of national target groups for monovalent 2009 pandemic influenza vaccine and trivalent seasonal influenza vaccines in 2009-10 and 2010-11
    Sophia Ng
    Peng Wu
    Hiroshi Nishiura
    Dennis KM Ip
    Esther ST Lee
    Benjamin J Cowling
    BMC Infectious Diseases, 11
  • [8] Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients
    Undine Ott
    Andreas Sauerbrei
    Jeannette Lange
    Anna Schäfler
    Mario Walther
    Gunter Wolf
    Peter Wutzler
    Roland Zell
    Andi Krumbholz
    Medical Microbiology and Immunology, 2012, 201 : 297 - 302
  • [9] Surveillance of adverse events following vaccination in the French armed forces, 2011-2012
    Mayet, A.
    Duron, S.
    Meynard, J. -B.
    Koeck, J. -L.
    Deparis, X.
    Migliani, R.
    PUBLIC HEALTH, 2015, 129 (06) : 763 - 768
  • [10] A cluster of nonspecific adverse events in a military reserve unit following pandemic influenza A (H1N1) 2009 vaccination-Possible stimulated reporting?
    McNeil, Michael M.
    Arana, Jorge
    Stewart, Brock
    Hartshorn, Mary
    Hrncir, David
    Wang, Henry
    Lamias, Mark
    Locke, Michael
    Stamper, John
    Tokars, Jerome I.
    Engler, Renata J.
    VACCINE, 2012, 30 (14) : 2421 - 2426